Friday, March 31, 2023
Clinical Advances in
The treatment of HR-positive breast cancer is undergoing significant changes with the introduction of novel targeted therapies such as cyclin-dependent kinase (CDK) 4 and 6 inhibitors that are already demonstrating improvements in patient outcomes. As different agents become available and are increasingly integrated into treatment algorithms, clinical challenges are created regarding rational treatment selection, appropriate patient selection, and sequencing of treatments.
Supported by an independent educational sponsorship from
See All
The Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib in Combination With Letrozole Versus Letrozole Alone as First-Line Treatment of Oestrogen Receptor-Positive, HER2-Negative, Advanced Breast Cancer (PALOMA-1/TRIO-18): A Randomised Phase 2 Study
Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3)
See All
Steering Committee Chair
Centre for Experimental Cancer Medicine
St. Bartholomew Hospital
Chair of Cancer Medicine and Honorary Consultant in Medical Oncology Barts Cancer Institute
Queen Mary University London
London, United Kingdom
Professor, University of Milano; Head, European Institute of Oncology, Milan, Italy
Celebrating Womens Chair in Breast Cancer
Research
Baylor University Medical Center
Texas Oncology
US Oncology
Dallas, Texas, United States
Head, Medical Oncology, CHU Sart Tilman Liège; Professor of Medical Oncology, Liège University, Liège, Belgium
Chair German Breast Group, Sana Kliniken Offenbach, Breast Cancer Center; Associate Professor, University Frankfurt am Main, Frankfurt, Germany
Steering Committee Chair
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Eisai Co., Ltd; Pfizer Inc; Puma Biotechnology
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Novartis Pharmaceuticals Corporation; Pfizer Inc.; Roche
Served as a speaker or a member of a speakers bureau for: Pfizer Inc.; Roche
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Pfizer Inc.
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Lilly; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Puma Biotechnology; Roche
Served as a speaker or a member of a speakers bureau for: Celgene Corporation; Lilly; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Roche
Received grants for clinical research from: Amgen Inc.; Bristol-Myers Squibb Company; Novartis Pharmaceuticals Corporation; Roche
Has disclosed the following relevant financial relationships:
Received grants for clinical research from: Amgen Inc.; AstraZeneca; Celgene Corporation; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Roche; Teva Europe